Beovu (brolucizumab)
- Region
- 🇪🇺 EU
- Active substance
- brolucizumab
- Company
- Novartis Europharm Limited
- Status
- Authorised
- Therapeutic area
- Wet Macular Degeneration
- CHMP opinion
- Thu 12 Dec 2019
- EU approval
- Thu 13 Feb 2020
- Application
- EMEA/H/C/004913
- ATC
- S01
- Official record
- www.ema.europa.eu
Indication
Beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Regulatory milestones
No milestones recorded in the last year.
Follow Beovu
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.